Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
Spyre Therapeutics (SYRE) has drawn attention after recent trading left the stock with a 1-day return showing a 2.5% decline, a 3-month gain of 20.6%, and a 1-year total return of 127%. See our latest analysis for Spyre Therapeutics. The recent 1-day share price decline sits against a much stronger backdrop, with the 90-day share price return of 20.6% and 1-year total shareholder return of 127% pointing to momentum that has cooled slightly in the past month but remains strong over the longer term. If you are comparing Spyre Therapeutics with other high growth stories in healthcare, this is a good moment to scan for 36 healthcare AI stocks With Spyre Therapeutics still loss making, trading around $41.25 and sitting roughly 47% below the average analyst price target of $60.79, the key question is whether this gap signals a buying opportunity or whether markets are already pricing in future growth. Price to Book of 5.8x: Is it justified? On a P/B of 5.8x, Spyre Therapeutics
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) had its price target raised by Stifel Nicolaus from $70.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms [Seeking Alpha]Seeking Alpha
- Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 3/5/26 - Form EFFECT
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SYRE's page on the SEC website